Amgen touts two cancer study wins with DLL3, Lumakras amid second-quarter earnings update
Two cancer drugs succeeded in mid- or late-stage clinical studies, Amgen said Thursday in its second-quarter earnings announcement.
“Momentum is building in the pipeline,” Amgen CFO Peter Griffith told Endpoints News, adding the biotech plans to discuss both datasets with regulators, calling a study for the DLL3-targeting drug tarlatamab “potentially registrational.”
In a Phase II small cell lung cancer study, tarlatamab showed a durable response rate that “substantially exceeds what was previously reported in the Phase I study,” the $123 billion drugmaking giant said in its midyear update. But specific data were sparse in Thursday’s release; Amgen said it will present more detailed results at an upcoming medical conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.